By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a ...

The following is a summary of “Analysis of the Incidence and Outcomes of Breast Cancer in Women with Schizophrenia,” published in the November 2024 issue of Surgery by Den et al. Worldwide, breast ...

Recently, second-generation antipsychotics (SGAs), olanzapine plus fluoxetine, quetiapine extended release and aripiprazole have clearly demonstrated efficacy in the treatment of MDD patients ...

Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...

Typically, they are treated with antipsychotics. But those have side effects including severe constipation, confusion and ...

Response Pharmaceuticals believes its experimental drug can lessen the persistent weight gain associated with antipsychotics.

Background: Hallucinations are prevalent in schizophrenia and related psychotic disorders and may have severe consequences for the affected patients. Antipsychotic drug trials that specifically ...

The state auditor report found poor record keeping and a lack of therapy to accompany psychotropic medications.